109 related articles for article (PubMed ID: 28667027)
21. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
22. Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines.
Yunos NM; Beale P; Yu JQ; Strain D; Huq F
Anticancer Res; 2010 Oct; 30(10):4025-37. PubMed ID: 21036717
[TBL] [Abstract][Full Text] [Related]
23. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
24. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
25. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
26. An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.
Blumenthal RD; Leone E; Goldenberg DM; Rodriguez M; Modrak D
Int J Cancer; 2004 Jan; 108(2):293-300. PubMed ID: 14639618
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.
Chobanian NH; Greenberg VL; Gass JM; Desimone CP; Van Nagell JR; Zimmer SG
Anticancer Res; 2004; 24(2B):539-45. PubMed ID: 15160991
[TBL] [Abstract][Full Text] [Related]
28. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.
Alagkiozidis I; Facciabene A; Tsiatas M; Carpenito C; Benencia F; Adams S; Jonak Z; June CH; Powell DJ; Coukos G
J Transl Med; 2011 May; 9():77. PubMed ID: 21609494
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
30. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
31. Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.
Yuan J; Kang JL; Liao H; Wang XX; Nie ML; Shuai R; Deng C
Anticancer Agents Med Chem; 2015; 15(10):1308-16. PubMed ID: 26118713
[TBL] [Abstract][Full Text] [Related]
32. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
33. Bikunin plus paclitaxel markedly reduces tumor burden and ascites in mouse model of ovarian cancer.
Kobayashi H; Yagyu T; Inagaki K; Kondo T; Suzuki M; Kanayama N; Terao T
Int J Cancer; 2004 May; 110(1):134-9. PubMed ID: 15054878
[TBL] [Abstract][Full Text] [Related]
34. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
36. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
Engle DB; Belisle JA; Gubbels JA; Petrie SE; Hutson PR; Kushner DM; Patankar MS
Gynecol Oncol; 2009 Mar; 112(3):631-6. PubMed ID: 19263582
[TBL] [Abstract][Full Text] [Related]
37. Synergistic interaction between paclitaxel and 8-chloro-adenosine 3',5'-monophosphate in human ovarian carcinoma cell lines.
McDaid HM; Johnston PG
Clin Cancer Res; 1999 Jan; 5(1):215-20. PubMed ID: 9918222
[TBL] [Abstract][Full Text] [Related]
38. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells.
Zeng S; Chen YZ; Fu L; Johnson KR; Fan W
Clin Cancer Res; 2000 Sep; 6(9):3766-73. PubMed ID: 10999771
[TBL] [Abstract][Full Text] [Related]
39. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer.
Pashaei-Asl F; Pashaei-Asl R; Khodadadi K; Akbarzadeh A; Ebrahimie E; Pashaiasl M
Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1483-1487. PubMed ID: 28884602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
